Q3 EPS Estimates for Vor Biopharma Raised by HC Wainwright

Vor Biopharma Inc. (NASDAQ:VOR) – Equities researchers at HC Wainwright boosted their Q3 2025 EPS estimates for shares of Vor Biopharma in a report issued on Wednesday, October 29th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($3.98) per share for the quarter, up from their prior estimate of ($4.40). HC Wainwright has a “Buy” rating and a $52.00 price objective on the stock. HC Wainwright also issued estimates for Vor Biopharma’s Q4 2025 earnings at ($3.63) EPS, FY2025 earnings at $182.45 EPS, Q1 2026 earnings at ($3.53) EPS, Q2 2026 earnings at ($3.56) EPS, Q3 2026 earnings at ($3.60) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($8.41) EPS, FY2027 earnings at ($3.91) EPS and FY2029 earnings at $3.21 EPS.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

A number of other analysts also recently commented on VOR. Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. Zacks Research cut shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. Baird R W raised shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Finally, Stifel Nicolaus raised shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Vor Biopharma presently has an average rating of “Hold” and an average price target of $76.50.

Vor Biopharma Stock Performance

VOR opened at $24.11 on Friday. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80. The stock’s 50-day moving average is $33.75. The firm has a market cap of $165.15 million, a P/E ratio of -0.09 and a beta of 2.07.

Insider Activity at Vor Biopharma

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the transaction, the insider owned 32,781,209 shares of the company’s stock, valued at $50,483,061.86. This trade represents a 1.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Ra Capital Management, L.P. sold 260,859 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $29.39, for a total transaction of $7,666,646.01. Following the completion of the transaction, the director directly owned 15,104 shares of the company’s stock, valued at $443,906.56. This represents a 94.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,431,718 shares of company stock valued at $62,090,254 in the last three months. 0.45% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors have recently modified their holdings of VOR. Jane Street Group LLC purchased a new stake in shares of Vor Biopharma during the 1st quarter worth $140,000. OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma during the 1st quarter worth $100,000. Ariose Capital Management Ltd acquired a new stake in Vor Biopharma during the 3rd quarter worth $5,368,000. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Vor Biopharma during the 2nd quarter worth $66,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.